300357 我武生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)6.74014.89618.77321.17820.420
总资产报酬率 ROA (%)5.69213.03316.89019.11318.361
投入资产回报率 ROIC (%)6.46514.42118.50621.11319.116

边际利润分析
销售毛利率 (%)94.94895.26295.39395.73695.514
营业利润率 (%)40.17040.67244.21948.64550.537
息税前利润/营业总收入 (%)35.96437.31241.79945.91447.063
净利润/营业总收入 (%)33.22534.84137.46940.39842.396

收益指标分析
经营活动净收益/利润总额(%)96.10096.618102.51594.07993.968
价值变动净收益/利润总额(%)-0.0130.3600.6761.6001.236
营业外收支净额/利润总额(%)-1.1360.2840.6370.0230.340

偿债能力分析
流动比率 (X)6.6298.86714.37612.42221.129
速动比率 (X)6.3818.53413.90511.92420.256
资产负债率 (%)12.18510.0887.7697.0064.774
带息债务/全部投入资本 (%)0.7780.467-1.137-1.068--
股东权益/带息债务 (%)12,318.20320,537.318-8,595.943-9,315.131-7,211.267
股东权益/负债合计 (%)686.374845.4291,159.3041,282.5901,900.473
利息保障倍数 (X)-9.577-10.734-15.460-16.742-12.908

营运能力分析
应收账款周转天数 (天)68.80266.65065.73464.7110.000
存货周转天数 (天)501.276481.237445.498533.5620.000